Form D · Biotechnology

RayzeBio, Inc.

San Diego, CA · CIK 0001825367

Offering snapshot reported Sep 22, 2022 · SEC filing

Reported sold
$168M
Offering amount: $168M
Investors reported
18
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 25, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 22, 2022Initial$167,901,481No comparison18SEC filing
Jun 10, 2021Initial$108,530,514No comparison23SEC filing
Dec 1, 2020Initial$105,000,012No comparison17SEC filing
Nov 9, 2020Initial$15,000,000No comparison9SEC filing

Offering details

Securities
Equity, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-459654
Includes $8,146,506.12 of shares of Common Stock issued pursuant to a license agreement.
Preferred Stock can convert to the underlying shares of Common Stock.

Source: Form D, filed Sep 22, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Deborah Charych Executive
Jerel Davis Director
Aubrey Haddach Executive
Aaron Kantoff Director
Maha Katabi Director
Bong Koh Director
Arvind Kush Executive
Yi Larson Director
Alex Rosen Director
Aaron Royston Director
Ken Song Director, Executive
Mary Tagliaferri Director
Angie You Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5505 Morehouse Drive, Suite 300
San Diego, CA, 92121